Merck KGaA
Connections
Around the web
-
Oncothyreon A Speculative Buy
December 19th, 2012, Oncothyreon's (ONTY) shares fell roughly 50% as development partner Merck KGaA (MKGAY.PK) reported that L-BLP25 (or Stimuvax), a cancer immunotherapy that was being tested against non small-cell lung cancer (NSCLC), failed to meet its from Seeking Alpha Read more »
-
UPDATE: Wedbush Upgrades Oncothyreon on Statistically Significant Overall Survival Benefit
the report, Wedbush noted, "Merck KGaA(Merck Serono) reported new analysis of the Phase III data from the completed L-BLP25 (STIMUVAX) non-small cell lung cancer trial showing a strong treatment effect in the pre specified subgroup (n=806) of patients who from Benzinga.com Read more »
-
Merck KGaA Doesn't Rule Out Pursuing Lung-Cancer Vaccine
up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Merck KGaA (MRK) hasn’t ruled out pursuing its therapeutic cancer vaccine L-BLP25 after a trial showed the treatment prolonged the lives of a group of advanced lung cancer patients from Biospace Read more »
-
Merck KGaA Ups Commitment to MS Ventures to $129 Million
MS Ventures to significantly expand its investment activities while still focused on Merck Serono's core research areas. Merck will create a dedicated investment affiliate, MS Ventures, for these activities. "Biotech companies and their venture capital investors from Biospace Read more »
-
Merck Serono et Quintiles annoncent un partenariat de développement clinique innovant
L'une des clés de sa réussite tient au sens de l'innovation de ses employés. Les activités d'exploitation de Merck relèvent de Merck KGaA, dans laquelle la famille Merck détient une participation d'environ 70 % et les actionnaires libres près des 30 % restants. from Business Wire Read more »
